Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

You may be eligible if

• Inclusion:
• Male and female subjects ≥ 18 years of age with a histologic or cytologic diagnosis of Stage III or Stage IV (unresectable) melanoma
• Enrollment to cohort expansion will be limited to only those subjects whose tumors demonstrate the B-Raf V600E mutation
• ECOG ≤ 1
• Adequate organ \& marrow function
• Exclusion:
• Uncontrolled or significant cardiovascular disease
• Cohort expansion: Prior therapy with a RAF inhibitor